期刊文献+

中药及免疫治疗在白血病中的应用 被引量:6

The Application of Chinese Drugs and Immune Therapy in Leukemia
暂未订购
导出
摘要 白血病是肿瘤所致儿童和中青年死亡原因的第一位。目前,白血病的治疗主要包括化疗、造血干细胞移植、免疫治疗及包括中药在内的其他辅助治疗措施。其中,中药因其低毒性及综合作用等优势已在抗白血病的研究中逐逐受到重视。而免疫治疗被认为是继手术、化疗和放疗后第四大肿瘤治疗模式,目前被公认为是21世纪肿瘤综合治疗模式中最活跃。 Leukemia is the first reason causing death of children and youth. Currently, the treatment of leukemia includes chemotherapy, hematopoietic stem cell transplantation, immunotherapy and other ancillary treatments including Chinese drugs, among which Chinese drugs has been paid more attention to because of its low toxicitycomprehensive effect of anti-leukemia and other advantages. Immunotherapy is considered as the fourth largest cancer treatment model following the surgery, chemotherapy and radiotherapy, and is recog- nized as one of the most active and potential therapeutic methods for tumors in the 21^st century.
出处 《医学综述》 2014年第1期59-62,共4页 Medical Recapitulate
关键词 中药 免疫治疗 白血病 Chinese drugs Immune therapy Leukemia
  • 相关文献

参考文献30

  • 1McLaughlin P, Grillo-L6pez A J, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lym- phoma:half of patients respond to a four-dose treatment program [ J ]. J Clin Oncol, 1998,16 ( 8 ) : 2825-2833.
  • 2Parikh SA, Keating M J, O' Brien S, et al. Frontline ch therapy with fludarabine, cyclophosphamide, alemtuzumab, and rit- uximab for high-risk chronic lymphocytic leukemia [ J ]. Blood, 2011,118(8) :2062-2068.
  • 3Feldman E, KalayeioM, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 mono- clonal antibody HUM195[ J]. Leukemia,2003,17(2) :314-318.
  • 4Dearden CE, Matures E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [ J ]. Blood, 2001,98(6) :1721-1726.
  • 5Keating M J, Flinn I, Jain V,et al. Therapeutic role of alemtuzumab ( CAMPATH-1 H)in patients who have failed fludarabine : results of a large international study[J]. Blood,2002,99(10) :3554-3561.
  • 6Lundin J,Kimby E,Bjorkholm M,et al. Phase 1I trial of subcuta- neous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH- 1 H)as first-line treatment for patients with B-cell chronic lympho- cytic leukaemia(B-CLL) [ J ]. Blood ,2002,100 ( 3 ) :768-773.
  • 7Mosmann T. Rapid colorimetric assay for cellular growth and sur- vival: application to proliferation and cytotoxicity assay [ J ]. J Immunol Methods, 1983,65 ( 1 ) :55-63.
  • 8Taksin AL, Legrand O, Raffoux E, et al. Hish efficacy and safety profile of fraetionated doses of Mylotarg ag induction therapy inpatients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group[ J]. Leukemia,2007,21 (1) :66-71.
  • 9Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlu- sire disease in patients who under go myeloablative allogeneic stem cell transplantation [ J ]. Blood,2003,102 (5) : 1578-1582.
  • 10Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-1abeled ibritumomab tiuxetan radioimmunothera- py versus rituximab immunotherapy for patients with relapsed or refractorylow-grade,follicular,or transforuled B-cell non-Hodgkin's lymphoma [ J ]. J Clin Onco1,2002,20 ( 10 ) :2453-2463.

二级参考文献32

共引文献826

同被引文献44

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部